Lesinurad Intermediate CAS 1533519-84-4 Purity >99.0% (HPLC)
Shanghai Ruifu Chemical Co., Ltd. is the leading manufacturer of 4-(4-Cyclopropylnaphthalen-1-yl)-1H-1,2,4-Triazole-5(4H)-Thione (CAS: 1533519-84-4) with high quality, intermediate of Lesinurad (CAS: 878672-00-5). Ruifu Chemical can provide worldwide delivery, competitive price, excellent service, small and bulk quantities available. Purchase Lesinurad Intermediates, Please contact: alvin@ruifuchem.com
| Chemical Name | 4-(4-Cyclopropylnaphthalen-1-yl)-1H-1,2,4-Triazole-5(4H)-Thione |
| Synonyms | 4-(4-Cyclopropylnaphthalen-1-yl)-4H-1,2,4-Triazole-3-Thiol; 4-(4-Cyclopropyl-1-Naphthalenyl)-2,4-Dihydro-3H-1,2,4-Triazole-3-Thione; Lesinurad INT3; Lesinurad Impurity 20 |
| Stock Status | In Stock, Commercial Production |
| CAS Number | 1533519-84-4 |
| Molecular Formula | C15H13N3S |
| Molecular Weight | 267.35 g/mol |
| Boiling Point | 435.2±38.0℃ |
| Density | 1.41±0.10 g/cm3 |
| COA & MSDS | Available |
| Origin | Shanghai, China |
| Category | Intermediate of Lesinurad (CAS: 878672-00-5) |
| Brand | Ruifu Chemical |
| Items | Inspection Standards | Results |
| Appearance | Off-White Powder | Off-White Powder |
| Water by Karl Fischer | <0.50% | 0.10% |
| Loss on Drying | <0.50% | 0.40% |
| Residue on Ignition | <0.50% | 0.15% |
| Purity / Analysis Method | >99.0% (HPLC) | 99.8% |
| Infrared Spectrum | Consistent with Structure | Complies |
| 1H NMR Spectrum | Consistent with Structure | Complies |
| Conclusion | The product has been tested & complies with the given specifications | |
Package: Bottle, Aluminium foil bag, 25kg/Cardboard Drum, or according to customer's requirement.
Storage Condition: Keep the container tightly closed and store in a cool, dry (2~8℃) and well-ventilated warehouse away from incompatible substances. Protect from light and moisture.
Shipping: Deliver to worldwide by air, by FedEx / DHL Express. Provide fast and reliable delivery.
How to Purchase? Please contact Dr. Alvin Huang: sales@ruifuchem.com or alvin@ruifuchem.com
15 Years Experience? We have more than 15 years of experience in the manufacture and export of a wide range of high quality pharmaceutical intermediates or fine chemicals.
Main Markets? Sell to domestic market, North America, Europe, India, Korea, Japanese, Australia, etc.
Advantages? Superior quality, affordable price, professional services and technical support, fast delivery.
Quality Assurance? Strict quality control system. Professional equipment for analysis include NMR, LC-MS, GC, HPLC, ICP-MS, UV, IR, OR, K.F, ROI, LOD, MP, Clarity, Solubility, Microbial limit test, etc.
Samples? Most products provide free samples for quality evaluation, shipping cost should be paid by customers.
Factory Audit? Factory audit welcome. Please make an appointment in advance.
MOQ? No MOQ. Small order is acceptable.
Delivery Time? If within stock, three days delivery guaranteed.
Transportation? By Express (FedEx, DHL), by Air, by Sea.
Documents? After sales service: COA, MOA, ROS, MSDS, etc. can be provided.
Custom Synthesis? Can provide custom synthesis services to best fit your research needs.
Payment Terms? Proforma invoice will be sent first after confirmation of order, enclosed our bank information. Payment by T/T (Telex Transfer), PayPal, Western Union, etc.
L-Phenylalanine (H-Phe-OH) (CAS: 63-91-2) is used as an intermediate in the synthesis of Lesinurad (CAS: 878672-00-5). Lesinurad is a selective inhibitor of uric acid reabsorption which is used in combination with other agents in the therapy of gout. Lesinurad (brand name Zurampic) is the first selective uric acid reabsorption inhibitor (SURI) approved by the FDA. It acts by inhibiting the urate transporter, URAT1, which is responsible for the majority of the renal reabsorption of uric acid. Lesinurad is a urate transporter inhibitor for treating hyperuricemia associated with gout in patients who have not achieved target serum uric acid levels with a xanthine oxidase inhibitor alone. It received FDA approval on December 22, 2015. The European Commission granted a marketing authorisation valid throughout the European Union on 18 February 2016.
